Changeflow GovPing Government & Legislation EC SCENIHR Final Opinion on Dental Amalgam Safety
Routine Notice Added Final

EC SCENIHR Final Opinion on Dental Amalgam Safety

Favicon for www.regulations.gov Regulations.gov Final Notices
Detected
Email

Summary

The European Commission's Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) has issued a Final Opinion on the safety of dental amalgam in medical and dental practice. The opinion was submitted to the FDA docket as document FDA-2026-P-4271-0019 on Regulations.gov. The full text of the opinion is restricted due to copyright. Healthcare providers and dental professionals should monitor the FDA docket for updates or access the opinion through the European Commission.

Published by EC SCENIHR on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

This feed pulls every final notice posted to regulations.gov across all federal agencies, around 240 a month. Final notices are the binding step in the federal rulemaking cycle: a final rule, a no-action determination, a self-regulatory organization rule change, or a procedural notice that takes effect on publication. Watch this for the actionable end of the rulemaking pipeline rather than the proposed-and-comment phase. GovPing publishes each notice with the issuing agency, docket ID, effective date where stated, and document type. Recent examples include Nasdaq ISE auction rule changes and an NYSE proposal enabling tokenized securities trading under the DTC pilot.

What changed

The European Commission's SCENIHR has published a Final Opinion on dental amalgam safety. The opinion represents the scientific committee's assessment of health risks associated with dental amalgam use. The document was submitted to the FDA's public docket on Regulations.gov, indicating FDA's interest in this scientific assessment as part of its regulatory consideration of dental materials.

Healthcare providers and dental professionals should monitor the FDA docket for related regulatory developments. The opinion may inform future FDA guidance or policy regarding dental amalgam, although SCENIHR opinions themselves are scientific assessments rather than binding regulatory requirements.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

Content Restricted

Reason Restricted: Copyrighted

Get daily alerts for Regulations.gov Final Notices

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EC SCENIHR.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EC SCENIHR
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
FDA-2026-P-4271-0019

Who this affects

Applies to
Healthcare providers
Industry sector
6211 Healthcare Providers
Activity scope
Scientific opinion Dental materials review
Geographic scope
European Union EU

Taxonomy

Primary area
Healthcare
Operational domain
Healthcare
Topics
Public Health Medical Devices

Get alerts for this source

We'll email you when Regulations.gov Final Notices publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!